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A new arenavirus in a cluster of fatal 
transplant-associated diseases
Renal-transplant recipients are susceptible to a variety of infections, 
including BK and polyoma viruses and the cytomegalovirus, that 
have greater clinical signiﬁcance than those seen in the immuno-
competent population. A new report comments on the occurrence 
of an arenavirus in three recipients of organs from a single donor. 
The donor, whose exposure to the virus was thought to be related 
to a new hamster present in his home, provides signiﬁcant detail 
on the investigation and discovery of arenavirus infection. The 
three patients received two kidneys and a liver from a donor who 
died of cerebral hemorrhage 10 days after returning to Australia 
from a 3-month visit to the former Yugoslavia, where he traveled 
in rural areas. The three recipients all developed febrile illnesses 
with varying degrees of encephalopathy and died 4–6 weeks after 
transplantation. The methodology used unbiased high-through-
put sequencing, yielding 103,632 sequences, of which 14 repre-
sented an Old World arenavirus. This arenavirus was related to 
lymphocytic choriomeningitis viruses. Polymerase chain reac-
tion assays conﬁrmed the presence of the virus in the kidneys, 
liver, blood, and cerebrospinal ﬂuid of the recipients. Immuno-
histochemistry demonstrated an arenavirus antigen in the liver 
and kidney transplants in the recipients (Figure). The prototype 
of arenaviruses is the lymphocytic choriomeningitis virus, which 
is typically asymptomatic or associated with a mild illness. The 
arenaviruses are negative-strand RNA viruses in rodents that can 
be transmitted to humans through exposure to infected urine. 
Although this article is not the ﬁrst to report human-to-human 
transmission of an arenavirus,1 it is important because it describes 
the methods that may be used when investigating an illness in 
which the ‘typical’ pathogens have all been ruled out. Also, if the 
scope of these infections expands in the future, this report may 
provide additional criteria for screening deceased donors. (N Engl 
J Med advance online publication, 6 February 2008; doi:10.1056/
NEJMoa073785)
Lynda Szczech
1N Engl J Med 2006; 354: 2235–2249
Intensive therapy and mortality in 
patients with type 2 diabetes
In 1993, the Diabetes Control and Complications Trial demon-
strated that intensive therapy eﬀectively delays the onset and slows 
the progression of diabetic retinopathy, nephropathy, and neuropa-
thy in patients with type 2 diabetes.1
The Steno-2 study, published in 2003, looked at a similar ques-
tion among non-insulin-dependent diabetics.2 This trial rand-
omized 160 white Danish patients with type 2 diabetes to receive 
either conventional multifactorial treatment, consistent with the 
guidelines of the Danish Medical Association, or intensiﬁed, 
target-driven therapy, to achieve a glycated hemoglobin level of 
less than 6.5%, a fasting serum total cholesterol level of less than 
175 mg/dl, a fasting serum triglyceride level of less than 150 mg/dl, 
a systolic blood pressure of less than 13 mm Hg, and a diastolic 
blood pressure of less than 80 mm Hg. Subjects were treated with 
blockers of the renin–angiotensin system as well as low-dose aspi-
rin. Subjects had a mean follow-up of 7.8 years. The intensiﬁed-
therapy group had a lower mortality rate, but this did not reach 
statistical signiﬁcance, presumably because of the low power of 
the small number of participants. This group also had lower systo-
lic and diastolic blood pressure, urinary albumin excretion, and 
serum cholesterol, triglyceride, and glycosylated hemoglobin val-
ues. Additional follow-up took place 5.5 years after the initial trial 
ended. As would be expected, at long-term follow-up, many of 
the diﬀerences between the treatment groups greatly diminished, 
such as lower urinary albumin excretion, blood pressure, choles-
terol, and glycated hemoglobin. However, some factors, including 
exercise duration, remained diﬀerent and closer to goal in the 
intensive-therapy group. The group that received intensive ther-
apy, in spite of the waning diﬀerences in some parameters, also 
had signiﬁcantly fewer events of cardiovascular death, all-cause 
death, stroke, myocardial infarction, coronary revascularization, 
and amputation. Further, nephropathy, deﬁned as greater than 
300 mg of albuminuria per 24 hours, was present in 20 individuals 
in the intensive-therapy group as compared with 37 individuals 
in the conventional-therapy group (P = 0.004).
Recently, intensive therapy for glycemic control (A1c < 6%) was 
stopped during a large, ongoing trial with similar design called the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. 
The Data and Safety Monitoring Board, which monitors patient 
safety in trials, recommended stopping intensive therapy when it 
was found to cause a higher risk of death in patients with type 2 
diabetes.3 An in-depth comparison of the Steno-2 and ACCORD 
trials is needed, given that their conclusions are inconsistent.
a
b
The distribution of the arenavirus antigen is shown in the liver (a) 
and kidney (b) of recipient 1.
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Before discontinuation of the intensive-therapy arm of the 
ACCORD trial, the message of the Steno-2 study could have been 
that patients with type 2 diabetes who improve their benchmarks 
of care will continue to improve after the study treatment has 
ended. In addition, the message for nephrologists might have been 
to expand our focus beyond albuminuria as the single risk fac-
tor for progression to nephropathy to consider all cardiovascular 
risk factors. As an understanding of the results and implications of 
ACCORD develops, these messages may be maintained. (N Engl 
J Med 2008; 358: 580–591)
Lynda Szczech
1N Engl J Med 1993; 329: 977–998. 2N Engl J Med 2003; 348: 383–393. 3NIH News, 
National Institutes of Health, http://public.nhlbi.nih.gov/newsroom/home/
GetPressRelease.aspx?id=2551, accessed 18 February 2008.
Aprotinin and renal dysfunction in 
patients undergoing on- and off-
pump cardiac surgery
Aprotinin is used during cardiac surgery for its blood-saving 
eﬀects. However, reports suggest a possible association between 
the use of this drug and increased renal dysfunction and mortal-
ity. Mouton et al. examined this possible relationship, including 
on-pump versus oﬀ-pump surgery and co-medication with angi-
otensin-converting enzyme (ACE) inhibitors. The authors con-
ducted a retrospective, observational study that included 9,875 
patients undergoing on-pump or oﬀ-pump cardiac surgery from 
1 January 2000 to 30 September 2007. Of these patients, 9,106 were 
included in the analysis. Using propensity-adjusted, multivariate 
staged logistic regression, they analyzed the incidence of renal 
dysfunction in patients receiving aprotinin, tranexamic acid, or 
no antiﬁbrinolytic treatment in the presence or absence of preop-
erative ACE inhibitor treatment after undergoing either on-pump 
or oﬀ-pump surgery. In 5,434 patients undergoing on-pump car-
diac surgery, the odds ratio (OR) between aprotinin and risk of 
renal dysfunction was 1.81 (95% conﬁdence interval 0.79–4.13, 
P = 0.162) without ACE inhibitor and 1.73 (0.56–5.32, P = 0.342) 
with ACE inhibitor. In the 848 patients who took ACE inhibitors 
and underwent oﬀ-pump cardiac surgery, aprotinin was associated 
with increased risk of renal dysfunction (OR 2.87 (1.25–6.58), P = 
0.013). These results show that aprotinin seems to be safe during 
on-pump cardiac surgery. However, in the subgroup of patients 
who took ACE inhibitors and underwent oﬀ-pump cardiac sur-
gery, aprotinin might be associated with increased postoperative 
renal dysfunction. Concerns about this possible association are not 
supported by published randomized, controlled trials. The authors 
recommend that patients discontinue use of an ACE inhibitor 
before undergoing elective oﬀ-pump cardiac surgery, particularly 
patients with a history of renal impairment. It is worth noting that 
the international ﬁeld of cardiac anesthesia and surgery faces con-
troversy regarding the use of aprotinin. In the United Kingdom, 
the European Commission is conducting a full review of the risks 
and beneﬁts of aprotinin. (Lancet 2008; 371: 475–482; doi:10.1016/
S0140-6736(08)60237-8)
Marc De Broe
Mesenchymal–epithelial transition 
in Zeb1 mutant mice
Epithelial-to-mesenchymal transition (EMT) is a prominent 
feature during embryogenesis and development of metastatic 
phenotype in cancer and a variety of diseases with ﬁbrotic 
response to injury. In the kidney, a variety of studies have con-
clusively shown that several tubular epithelial cells can undergo 
EMT. Indeed, EMT is such a prominent response to kidney 
injury that the reverse event, mesenchymal–epithelial transi-
tion, could be involved in renal repair. During embryogenesis, 
in cancer metastasis and in ﬁbrotic responses to injury, EMT is 
thought to be driven by transforming growth factor-β (TGFβ) 
family members. Zinc finger E-box binding homeobox 1 
(Zeb1) binds a set of E-box-like elements and can act as a 
transcriptional repressor. Overexpression of Zeb1 in cancer is 
associated with repression of E-cadherin and EMT, but Zeb1 
can also serve as a transcriptional activator, particularly toward 
mesenchymal genes. During embryogenesis, Zeb1 is expressed 
in proliferating mesenchymal and neural progenitors, and Zeb1 
mutation leads to several craniofacial abnormalities. Liu et al. 
now report that in Zeb1-null embryos, E-cadherin became 
ectopically expressed. In contrast, vimentin expression was 
lost from appropriate sites. Further, in isolated embryonic 
ﬁbroblasts from wild-type, heterozygous, and Zeb1-null lit-
termates, E-cadherin was not detected on the wild-type cells 
but was evident on mutant cells (Figure). Interestingly, some of 
the ﬁbroblasts displayed abnormal epithelial-like morphology 
in both the null and heterozygous cell populations (Figure). 
However, E-cadherin was evident uniformly throughout the 
Zeb1-null cell population and was not conﬁned to cells exhibit-
ing epithelial-like morphology. Because TGFβ drives EMT by 
inducing mesenchymal genes such as vimentin and repress-
ing epithelial genes such as E-cadherin, the authors examined 
whether Zeb1 is important for TGFβ-mediated EMT. They 
found that vimentin induced by TGFβ was lost in the null 
ﬁbroblasts. These results suggest that TGFβ represses E-cad-
herin through induction of Zeb1 and that Zeb1 is an important 
regulator of the balance between epithelial and mesenchymal 
gene expression in vivo. (Development 2008; 135: 579–588; 
doi:10.1242/10.1242/dev.007047)
Juan Oliver
Fibroblasts from Zeb1 mutant mice express E-cadherin and display 
epithelial-like morphology. Scale bars, 25 µm.
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